RDY · NYSE · CIK 0001135951

DR REDDYS LABORATORIES LTD

DR REDDYS LABORATORIES LTD’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 26, 2026. In fiscal 2025 (year ended Mar 31, 2025) it reported revenue of INR 325.5B and net income of INR 57.2B, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025

INR 325.5B

Net income, FY2025

INR 57.2B

Form 4 filings on record, past 12 months

Company overview

Legal name (as filed): DR REDDYS LABORATORIES LTD
Ticker: RDY
SEC Central Index Key (CIK): 0001135951
Industry (SIC): Pharmaceutical Preparations (code 2834)
Business address: HYDERABAD
State or country of incorporation: India
Fiscal year ends: March 31
SEC filer category: Large accelerated filer
Position in SEC ticker list: #862 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from DR REDDYS LABORATORIES LTD’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in INR; the fiscal year is named for the calendar year in which it ends.

Revenue

Net income

RDY annual results
Item	FY2021 ended Mar 31, 2021	FY2022 ended Mar 31, 2022	FY2023 ended Mar 31, 2023	FY2024 ended Mar 31, 2024	FY2025 ended Mar 31, 2025
Revenue	INR 189.7B	INR 214.4B	INR 245.9B	INR 279.2B	INR 325.5B
Net income	INR 17.2B	INR 23.6B	INR 45.1B	INR 55.7B	INR 57.2B
Diluted EPS	INR 103.65	INR 141.69	INR 54.17	INR 66.80	INR 67.78
Total assets	INR 265.5B	INR 292.8B	INR 321.9B	INR 387.5B	INR 493.0B
Cash and equivalents	INR 14.8B	INR 14.9B	INR 5.8B	INR 7.1B	INR 14.7B

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

RDY latest annual, quarterly, current and proxy reports
Filed	Form	What it is	Original
May 29, 2026	20-F	Annual report of a foreign private issuer· period Mar 31, 2026	Document · Index
Oct 26, 2026	6-K	Report of a foreign private issuer· period Oct 24, 2026	Document · Index

Recent SEC filings

The 40 newest documents filed by or about DR REDDYS LABORATORIES LTD, by form type:

6-K ×40

RDY recent filings
Filed	Form	What it is	Original
Oct 26, 2026	6-K	Report of a foreign private issuer· period Oct 24, 2026	Document · Index
Oct 26, 2026	6-K	Report of a foreign private issuer· period Oct 24, 2026	Document · Index
Oct 23, 2026	6-K	Report of a foreign private issuer· period Oct 23, 2026	Document · Index
Oct 23, 2026	6-K	Report of a foreign private issuer· period Oct 23, 2026	Document · Index
Oct 23, 2026	6-K	Report of a foreign private issuer· period Oct 23, 2026	Document · Index
Oct 23, 2026	6-K	Report of a foreign private issuer· period Oct 23, 2026	Document · Index
Oct 21, 2026	6-K	Report of a foreign private issuer· period Oct 21, 2026	Document · Index
Oct 14, 2026	6-K	Report of a foreign private issuer· period Oct 14, 2026	Document · Index
Oct 8, 2026	6-K	Report of a foreign private issuer· period Oct 8, 2026	Document · Index
Oct 7, 2026	6-K	Report of a foreign private issuer· period Oct 7, 2026	Document · Index
Oct 5, 2026	6-K	Report of a foreign private issuer· period Oct 3, 2026	Document · Index
Sep 22, 2026	6-K	FORM 6K· period Sep 22, 2026	Document · Index
Sep 21, 2026	6-K	FORM 6K· period Sep 21, 2026	Document · Index
Sep 18, 2026	6-K	Report of a foreign private issuer· period Sep 18, 2026	Document · Index
Sep 14, 2026	6-K	Report of a foreign private issuer· period Sep 11, 2026	Document · Index
Sep 10, 2026	6-K	Report of a foreign private issuer· period Sep 10, 2026	Document · Index
Sep 10, 2026	6-K	Report of a foreign private issuer· period Sep 10, 2026	Document · Index
Aug 26, 2026	6-K	Report of a foreign private issuer· period Aug 26, 2026	Document · Index
Aug 17, 2026	6-K	Report of a foreign private issuer· period Aug 14, 2026	Document · Index
Aug 17, 2026	6-K	Report of a foreign private issuer· period Aug 14, 2026	Document · Index
Aug 13, 2026	6-K	Report of a foreign private issuer· period Aug 13, 2026	Document · Index
Aug 10, 2026	6-K	RDY0934_6K· period Aug 7, 2026	Document · Index
Aug 3, 2026	6-K	Report of a foreign private issuer· period Aug 1, 2026	Document · Index
Jul 29, 2026	6-K	Report of a foreign private issuer· period Jul 29, 2026	Document · Index
Jul 29, 2026	6-K	Report of a foreign private issuer· period Jul 28, 2026	Document · Index
Jul 23, 2026	6-K	Report of a foreign private issuer· period Jul 23, 2026	Document · Index
Jul 23, 2026	6-K	Report of a foreign private issuer· period Jul 23, 2026	Document · Index
Jul 23, 2026	6-K	Report of a foreign private issuer· period Jul 23, 2026	Document · Index
Jul 23, 2026	6-K	Report of a foreign private issuer· period Jul 23, 2026	Document · Index
Jul 23, 2026	6-K	Report of a foreign private issuer· period Jul 23, 2026	Document · Index
Jul 22, 2026	6-K	Report of a foreign private issuer· period Jul 22, 2026	Document · Index
Jul 22, 2026	6-K	Report of a foreign private issuer· period Jul 22, 2026	Document · Index
Jul 22, 2026	6-K	Report of a foreign private issuer· period Jul 22, 2026	Document · Index
Jul 22, 2026	6-K	Report of a foreign private issuer· period Jul 22, 2026	Document · Index
Jul 22, 2026	6-K	Report of a foreign private issuer· period Jul 22, 2026	Document · Index
Jul 15, 2026	6-K	Report of a foreign private issuer· period Jul 15, 2026	Document · Index
Jul 13, 2026	6-K	Report of a foreign private issuer· period Jul 13, 2026	Document · Index
Jul 10, 2026	6-K	Report of a foreign private issuer· period Jul 10, 2026	Document · Index
Jul 9, 2026	6-K	Report of a foreign private issuer· period Jul 9, 2026	Document · Index
Jul 1, 2026	6-K	Report of a foreign private issuer· period Jun 30, 2026	Document · Index

Insider filing activity

0 Form 4 filings appear in DR REDDYS LABORATORIES LTD’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001135951 and XBRL company facts. DR REDDYS LABORATORIES LTD on EDGAR.
Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.